[
  {
    "ts": null,
    "headline": "Abbott Laboratories stock outperforms competitors on strong trading day",
    "summary": "Abbott Laboratories stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=072b4b153cd30fb8b63aecab13f5e23e3ad6d03da9f091d33a5d5e3a5f71e543",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752856380,
      "headline": "Abbott Laboratories stock outperforms competitors on strong trading day",
      "id": 136042292,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=072b4b153cd30fb8b63aecab13f5e23e3ad6d03da9f091d33a5d5e3a5f71e543"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Pressured by Weakness in Netflix and Health Insurers",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) today down -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.44%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.15%. September E-mini S&P futures (ESU25 ) are down -0.14%, and September E-mini Nasdaq futures (NQU25...",
    "url": "https://finnhub.io/api/news?id=2cf09540c35b5732b53f91482e528abd72f8dee8d226a52eb0442bbbda6eb1d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752852268,
      "headline": "Stocks Pressured by Weakness in Netflix and Health Insurers",
      "id": 136005384,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The S&P 500 Index ($SPX ) (SPY ) today down -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.44%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.15%. September E-mini S&P futures (ESU25 ) are down -0.14%, and September E-mini Nasdaq futures (NQU25...",
      "url": "https://finnhub.io/api/news?id=2cf09540c35b5732b53f91482e528abd72f8dee8d226a52eb0442bbbda6eb1d5"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Drops on Lower Full-Year Guidance",
    "summary": "We recently published These 10 Stocks Just Lost Their Spark. Abbott Laboratories (NYSE:ABT) is one of the worst-performing companies on Thursday. Abbott Laboratories declined by 8.52 percent on Thursday to end at $120.51 apiece as investors were disheartened by the lowering of its full-year guidance. For the full year, Abbott Laboratories (NYSE:ABT) now projects organic […]",
    "url": "https://finnhub.io/api/news?id=41c280310198c279514c8013ddc1420c514ddbbf1a816e923fb80729aa447395",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752850861,
      "headline": "Abbott Laboratories (ABT) Drops on Lower Full-Year Guidance",
      "id": 136005559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "We recently published These 10 Stocks Just Lost Their Spark. Abbott Laboratories (NYSE:ABT) is one of the worst-performing companies on Thursday. Abbott Laboratories declined by 8.52 percent on Thursday to end at $120.51 apiece as investors were disheartened by the lowering of its full-year guidance. For the full year, Abbott Laboratories (NYSE:ABT) now projects organic […]",
      "url": "https://finnhub.io/api/news?id=41c280310198c279514c8013ddc1420c514ddbbf1a816e923fb80729aa447395"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market News for Jul 18, 2025",
    "summary": "U.S. stocks ended higher on Thursday, with the S&P 500 and the Nasdaq closing at new record highs, as fresh economic data and solid earnings from a slew of big companies bolstered investors' faith in the economy.",
    "url": "https://finnhub.io/api/news?id=1202b59185b9a3382415668f96b5d444818350ee0fa38c935ace772b7a8104ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752846420,
      "headline": "Stock Market News for Jul 18, 2025",
      "id": 136005560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "U.S. stocks ended higher on Thursday, with the S&P 500 and the Nasdaq closing at new record highs, as fresh economic data and solid earnings from a slew of big companies bolstered investors' faith in the economy.",
      "url": "https://finnhub.io/api/news?id=1202b59185b9a3382415668f96b5d444818350ee0fa38c935ace772b7a8104ee"
    }
  },
  {
    "ts": null,
    "headline": "Are Medical Stocks Lagging  Abbott Laboratories (ABT) This Year?",
    "summary": "Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.",
    "url": "https://finnhub.io/api/news?id=c778def70f739bdb78af17f1bbdfb5ec9ed0e82c5a8cbe11b656e0e72efc695a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752846003,
      "headline": "Are Medical Stocks Lagging  Abbott Laboratories (ABT) This Year?",
      "id": 136005561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.",
      "url": "https://finnhub.io/api/news?id=c778def70f739bdb78af17f1bbdfb5ec9ed0e82c5a8cbe11b656e0e72efc695a"
    }
  },
  {
    "ts": null,
    "headline": "Snowflake initiated, Chipotle upgraded: Wall Street's top analyst calls",
    "summary": "Snowflake initiated, Chipotle upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=8be48837b8b917e4302db32c13e91c2e9a65e536e8c2efeb1ed2168093ca60db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752845897,
      "headline": "Snowflake initiated, Chipotle upgraded: Wall Street's top analyst calls",
      "id": 136003175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Snowflake initiated, Chipotle upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=8be48837b8b917e4302db32c13e91c2e9a65e536e8c2efeb1ed2168093ca60db"
    }
  },
  {
    "ts": null,
    "headline": "Down 9.0% in 4 Weeks, Here's Why Abbott (ABT) Looks Ripe for a Turnaround",
    "summary": "Abbott (ABT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.",
    "url": "https://finnhub.io/api/news?id=6420dfa1127dba8190f9b7effdaefd27916cc0b350a42a45d928eff9f3f79a0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752845702,
      "headline": "Down 9.0% in 4 Weeks, Here's Why Abbott (ABT) Looks Ripe for a Turnaround",
      "id": 136005565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (ABT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.",
      "url": "https://finnhub.io/api/news?id=6420dfa1127dba8190f9b7effdaefd27916cc0b350a42a45d928eff9f3f79a0e"
    }
  },
  {
    "ts": null,
    "headline": "Abbott upgraded after post-earnings selloff, hardware drag seen temporary",
    "summary": "Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE:ABT) to Buy from Hold, calling the market reaction to the company’s latest results “too punitive” and arguing that near-term headwinds in diagnostics are likely to ease.",
    "url": "https://finnhub.io/api/news?id=ea2aa3311a5f800701770dc8d9b8d3920e106e28a8bf2082d2373e8871b64662",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752843799,
      "headline": "Abbott upgraded after post-earnings selloff, hardware drag seen temporary",
      "id": 136005566,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE:ABT) to Buy from Hold, calling the market reaction to the company’s latest results “too punitive” and arguing that near-term headwinds in diagnostics are likely to ease.",
      "url": "https://finnhub.io/api/news?id=ea2aa3311a5f800701770dc8d9b8d3920e106e28a8bf2082d2373e8871b64662"
    }
  },
  {
    "ts": null,
    "headline": "Here's What to Expect From Charles River Laboratories' Next Earnings Report",
    "summary": "Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.",
    "url": "https://finnhub.io/api/news?id=48f8e7dcca88bd309e078da2af98851938df1d28e1612b691be990a5e11adbb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752840560,
      "headline": "Here's What to Expect From Charles River Laboratories' Next Earnings Report",
      "id": 136005568,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.",
      "url": "https://finnhub.io/api/news?id=48f8e7dcca88bd309e078da2af98851938df1d28e1612b691be990a5e11adbb5"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories: What's Behind The Q2 Earnings Slump?",
    "summary": "Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin guidance was cut. Learn more on ABT stock here.",
    "url": "https://finnhub.io/api/news?id=090a42d23e14c06f0a43593c1b99874b29f318c481860377c5749be7cfb9bccf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752828686,
      "headline": "Abbott Laboratories: What's Behind The Q2 Earnings Slump?",
      "id": 136001278,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399813281/image_1399813281.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin guidance was cut. Learn more on ABT stock here.",
      "url": "https://finnhub.io/api/news?id=090a42d23e14c06f0a43593c1b99874b29f318c481860377c5749be7cfb9bccf"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Q2 2025 Earnings Call Highlights: Strong Growth in Medical Devices ...",
    "summary": "Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds in diagnostics and international markets.",
    "url": "https://finnhub.io/api/news?id=289a794ed439ff99c802881f5a461a861a269102d57e5d19658c245ea609c695",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752822504,
      "headline": "Abbott Laboratories (ABT) Q2 2025 Earnings Call Highlights: Strong Growth in Medical Devices ...",
      "id": 136005569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds in diagnostics and international markets.",
      "url": "https://finnhub.io/api/news?id=289a794ed439ff99c802881f5a461a861a269102d57e5d19658c245ea609c695"
    }
  },
  {
    "ts": null,
    "headline": "ABT Q1 Deep Dive: Growth in Devices, Product Pipeline, and Tariff Mitigation Shape Outlook",
    "summary": "Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.4% year on year to $11.14 billion. Its non-GAAP profit of $1.26 per share was in line with analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=61c2df79829913ada39abbaf91c6ac65b5f0bd140a10c5ca6953b3fe6bbe092a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752816713,
      "headline": "ABT Q1 Deep Dive: Growth in Devices, Product Pipeline, and Tariff Mitigation Shape Outlook",
      "id": 136005570,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.4% year on year to $11.14 billion. Its non-GAAP profit of $1.26 per share was in line with analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=61c2df79829913ada39abbaf91c6ac65b5f0bd140a10c5ca6953b3fe6bbe092a"
    }
  }
]